secwatch.observer — SEC 8-K summary
======================================

Issuer:     PULSE BIOSCIENCES, INC. (PLSE)
CIK:        0001625101
Form:       8-K
Filed at:   2026-07-29T13:01:54+00:00
Accession:  0001437749-26-024758
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Pulse Biosciences surpasses enrollment midpoint in NANOPULSE-AF pivotal study
-----------------------------------------------------------------------------

- Study commenced April 2026; already past midpoint, enrolling at up to 30 sites including outside U.S.
- CMO David Kenigsberg cites strong enrollment trajectory reflecting investigator enthusiasm for nPulse technology.
- Top-enrolling investigator Frank Cuoco notes minimal learning curve and seamless workflow integration.
- Company to provide further commentary on study progress during August 6, 2026 earnings call.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1625101/000143774926024758/0001437749-26-024758-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1625101/000143774926024758/plse20260728_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-26-024758

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer